EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)

Alimu Dayimu, Avinash Gupta, Rubeta N Matin, Jenny Nobes, Ruth Board, Miranda Payne, Ankit Rao, Alberto Fusi, Sarah Danson, Bryony Eccles, Judith Carser, Ciara O'Hanlon Brown und 16 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2023.113455 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Alimu Dayimu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Unit, Department of Oncology, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansAgedProto-Oncogene Proteins B-rafQuality of LifePyridonesPyrimidinonesMitogen-Activated Protein Kinase KinasesAntineoplastic Combined Chemotherapy ProtocolsMutationImidazolesOximes

Stichwörter der Autor:innen

BRAFCirculating tumour DNAContinuous dosingDabrafenibIntermittent dosingMetastatic melanomaSchedulingTrametinib

Substanzen

Proto-Oncogene Proteins B-rafPyridonesPyrimidinonesMitogen-Activated Protein Kinase KinasesdabrafenibImidazolesOximestrametinibBRAF protein, human

Autor:innen und Institutionen

  • Clinical Trials Unit, Department of Oncology, University of Cambridge, Cambridge, UK.
  • The Christie NHS Foundation Trust, Manchester, UK.
  • Department of Dermatology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Department of Oncology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, UK.
  • Department of Oncology, Lancashire Teaching Hospitals NHS Trust, Preston, UK.
  • Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.

Förderung

  • Cancer Research UK

Zitieren

APA

Dayimu, A., Gupta, A., Matin, R. N., Nobes, J., Board, R., Payne, M., Rao, A., Fusi, A., Danson, S., Eccles, B., Carser, J., Brown, C. O., Steven, N., Bhattacharyya, M., Brown, E., Gonzalez, M., Highley, M., Pickering, L., Kumar, S., …, & Corrie, P. (2024). A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113455

Vancouver

Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, et al. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). European Journal of Cancer. 2024. doi:10.1016/j.ejca.2023.113455

BibTeX
@article{Dayimu2024,
  author = {Dayimu, Alimu and Gupta, Avinash and Matin, Rubeta N and Nobes, Jenny and Board, Ruth and Payne, Miranda and Rao, Ankit and Fusi, Alberto and Danson, Sarah and Eccles, Bryony and Carser, Judith and Brown, Ciara O'Hanlon and Steven, Neil and Bhattacharyya, Madhumita and Brown, Ewan and Gonzalez, Michael and Highley, Martin and Pickering, Lisa and Kumar, Satish and Waterston, Ashita and Burghel, George and Demain, Leigh and Baker, Eleanor and Wulff, Jerome and Qian, Wendi and Twelves, Sophie and Middleton, Mark and Corrie, Pippa},
  title = {A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2023.113455}
}
Kostenlos starten →